The Path to Clinical Proteomics Research: Integration of Proteomics, Genomics, Clinical Laboratory and Regulatory Science

키워드

참고문헌 (71)

1. Etzioni R, "The case for early detection", Nat Rev Cancer, 3, pp.243~252 (2003)
2. Anderson L, "Candidate-based proteomics in the search for biomarkers of cardiovascular disease", J Physiol, 563, pp.23~60 (2005)
3. Rifai N, "Protein biomarker discovery and validation: the long and uncertain path to clinical utility", Nat Biotechnol, 24, pp.971~983 (2006)
4. García-Foncillas J, "Proteomic analysis in cancer research: potential application in clinical use", Clin Transl Oncol, 8, pp.250~261 (2006)
5. Bouchal P, "Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS", MS) based quantitative proteomic analysis, 2009, pp.8, 362~373
6. Wiener MC, "Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures", Anal Chem, 76, pp.6085~6096 (2004)
7. Geiger T, "Super-SILAC mix for quantitative proteomics of human tumor tissue", Nat Methods, 7, pp.383~385 (2010)
8. Anderson L, "Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins", Mol Cell Proteomics, 5, pp.573~588 (2006)
9. Wang H, "Quantitative serum proteomics using dual stable isotope coding and nano LC-MS", MSMS, 2009, pp.8, 5412~5422
10. Lee J, "Microfluidic chips for mass spectrometry-based proteomics", J Mass Spectrom, 44, pp.579~593 (2009)
11. Pierobon M, "Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker", Clin Colorectal Cancer, 8, pp.110~117 (2009)
12. Ramachandran N, "Next-generation high-density self-assembling functional protein arrays", Nat Methods, 5, pp.535~538 (2008)
13. Beirne P, "Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis", Eur Respir J, 34, pp.1376~1382 (2009)
14. Kelleher MT, "The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients", Target Oncol, 4, pp.235~252 (2009)
15. Wang P, "The evolving role of mass spectrometry in cancer biomarker discovery", Cancer Biol Ther, 8, pp.1083~1094 (2009)
16. Whiteaker JR, "Head-to-head comparison of serum fractionation techniques", J Proteome Res, 6, pp.828~836 (2007)
17. Ernoult E, "A proteomic approach for plasma biomarker discovery with iTRAQ labeling and OFFGEL fractionation", J Biomed Biotechnol, 2010, pp.927917~ (2010)
18. Nirmalan NJ, "Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations", J Proteome Res, 10, pp.896~906 (2010)
19. Krishhan VV, "Multiplexed microbead immunoassays by flow cytometry for molecular profiling: basic concepts and proteomics applications", Crit Rev Biotechnol, 29, pp.29~43 (2009)
20. 차상원, "In Situ Proteomic Analysis of Human Breast Cancer Epithelial Cells Using Laser Capture Microdissection: Annotation by Protein Set Enrichment Analysis and Gene Ontology", MOLECULAR CELLULAR PROTEOMICS, 9(11), pp.2529~2544
21. Anderson KS, "Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer", J Proteome Res, 10, pp.85~96 (2011)
22. Bateman NW, "Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase", J Proteome Res, 9, pp.5311~5324 (2010)
23. Kristiansen TZ, "Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma", J Proteome Res, 7, pp.4670~4677 (2008)
24. An HJ, "A glycomics approach to the discovery of potential cancer biomarkers", Methods Mol Biol, 600, pp.199~213 (2010)
25. Choudhary C, "Decoding signalling networks by mass spectrometry-based proteomics", Nat Rev Mol Cell Biol, 11, pp.427~439 (2010)
26. Madian AG, "Profiling carbonylated proteins in human plasma", J Proteome Res, 9, pp.1330~1343 (2010)
27. Iwabata H, "Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies", Proteomics, 5, pp.4653~4664 (2005)
28. Ceroni A, "Systematic analysis of the IgG antibody immune response against varicella zoster virus (VZV) using a self-assembled protein microarray", Mol Biosyst, 6, pp.1604~1610 (2010)
29. Wong J, "Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays", J Immunol Methods, 350, pp.171~182 (2009)
30. Anderson NL, "The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum", Clin Chem, 56, pp.177~185 (2010)
31. Osterfeld SJ, "Multiplex protein assays based on real-time magnetic nanotag sensing", Proc Natl Acad Sci USA, pp.20637~20640 (2008)
32. Paulovich AG, "Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance", Mol Cell Proteomics, 9, pp.242~254 (2010)
33. Rudnick PA, "Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses", Mol Cell Proteomics, 9, pp.225~241 (2010)
34. Addona TA, "Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma", Nat Biotechnol, 27, pp.633~641 (2009)
35. Tabb DL, "Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry", J Proteome Res, 9, pp.761~776 (2010)
36. Rodriguez H, "Recommendations from the 2008 international summit on proteomics data release and sharing policy: the amsterdam principles", J Proteome Res, 8, pp.3689~3692 (2009)
37. Gloriam DE, "A community standard format for the representation of protein affinity reagents", Mol Cell Proteomics, 9, pp.1~10 (2010)
38. Xu X, "Selective detection of monohydroxy metabolites of polycyclic aromatic hydrocarbons in urine using liquid chromatography", triple quadrupole tandem mass spectrometry, 2004, pp.18, 2299~2308
39. Xu X, "Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry", Anal Chem, 79, pp.7813~7821 (2007)
40. James A, "Basic design of MRM assays for peptide quantification", Methods Mol Biol, 658, pp.167~185 (2010)
41. Kiyonami R, "Increased selectivity, analytical precision, and thro-ughput in targeted proteomics", Mol Cell Proteomics, 10 (2011)
42. Gerszten RE, "Integration of proteomic-based tools for improved biomarkers of myocardial injury", Clin Chem, 56, pp.194~201 (2010)
43. Kuhn E, "Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards", Proteomics, 4, pp.1175~1186 (2004)
44. Kuhn E, "Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry", Clin Chem, 55, pp.1108~1117 (2009)
45. Anderson NL, "Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA)", J Proteome Res, 3, pp.235~244 (2004)
46. 김용삼, "Quantitative Analysis of an Aberrant Glycoform of TIMP1 from Colon Cancer Serum by L-PHA-Enrichment and SISCAPA with MRM Mass Spectrometry", JOURNAL OF PROTEOME RESEARCH, 8, pp.4216~4224
47. Reid JD, "Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension", J Am Soc Mass Spectrom, 21, pp.1680~1686 (2010)
48. Jiang J, "An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis", Anal Chim Acta, 605, pp.70~79 (2007)
49. Mansfield E, "Food and drug administration regulation of in vitro diagnostic devices", J Mol Diagn, 7, pp.2~7 (2005)
50. "FDA/CDRH Public Meeting: oversight of Laboratory Developed Tests (LDTs)" (2010)[URL]
51. Shi L, "The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models", Nat Biotechnol, 28, pp.827~838 (2010)
52. "Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index assays"[URL]
53. "510(k) Substantial equivalence determination decision summary"[URL]
54. Rodriguez H, "Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics", Clin Chem, 56, pp.237~243 (2010)
55. Regnier FE, "Protein-based multiplex assays: mock presubmissions to the US food and drug administration", Clin Chem, 56, pp.165~171 (2010)
56. Pacini F, "Follow-up of differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 29(2), pp.492~496 (2002)
57. Saghari M, "Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan", Nucl Med Commun, 27, pp.567~572 (2006)
58. Spencer CA, "Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies", Clin Chem, 42, pp.661~663 (1996)
59. Spencer CA, "Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies", J Clin Endocrinol Metab, 89, pp.3702~3704 (2004)
60. Preissner CM, "Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays", J Clin Endocrinol Metab, 88, pp.3069~3074 (2003)
61. Hoofnagle AN, "Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry", Clin Chem, 54, pp.1796~1804 (2008)
62. Hoofnagle AN, "Peptide lost and found: internal standards and the mass spectrometric quantification of peptides", Clin Chem, 56, pp.1515~1517 (2010)
63. Ciccimaro E, "Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography", mass spectrometry, 2009, pp.81, 3304~3313
64. "CFR-Code federal regulations title 21"[URL]
66. Spitz MR, "The evolving discipline of molecular epidemiology of cancer", Carcinogenesis, 31, pp.127~134 (2010)
67. Rosa DD, "Molecular-targeted therapies: lessons from years of clinical development", Cancer Treat Rev, 34, pp.61~80 (2008)
68. Bredel M, "A network model of a cooperative genetic landscape in brain tumors", JAMA, 302, pp.261~275 (2009)
69. International Cancer Genome Consortium, "International network of cancer genome projects", Nature, 464, pp.993~998 (2010)
70. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways", Nature, 455, pp.1061~1068 (2008)
71. Verhaak RG, "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1", Cancer Cell, 17, pp.98~110 (2010)

관련 논문AI추천